Publication | Closed Access

PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft

Hematological MalignancyMedicineMyeloma CellsAnti-cancer AgentHomoharringtonine Antimyeloma ActivityPharmacologyCell BiologyTumor BiologyPi3k/akt Inhibitor Ly294002